Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 14, 2021

Primary Completion Date

March 18, 2023

Study Completion Date

March 18, 2023

Conditions
Pain, PostoperativeBrachial Plexus Block
Interventions
DRUG

Bupivacaine HCl

Subjects randomized to the continuous interscalene nerve block group will receive a loading dose of 15-20 mL bupivacaine HCl 0.5% followed by a continuous catheter infusion of bupivacaine 0.2% at 8 mL per hour for 72 hours.

DRUG

Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj

Subjects will receive a one-time interscalene nerve block injection of 5 mL of bupivacaine 0.5% (25 mg) admixed with 10 mL of liposomal bupivacaine (133 mg).

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05005260 - Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty | Biotech Hunter | Biotech Hunter